<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390867</url>
  </required_header>
  <id_info>
    <org_study_id>0152</org_study_id>
    <nct_id>NCT04390867</nct_id>
  </id_info>
  <brief_title>Temporally Optimized Patterned Stimulation (TOPS®) Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease</brief_title>
  <acronym>TOPS</acronym>
  <official_title>A Prospective, Randomized, Cross-Over Home-Use Study of TOPS® DBS for the Treatment of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deep Brain Innovations LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deep Brain Innovations LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test newly developed stimulation settings called Temporally Optimized
      Patterned Stimulation or TOPS, which can be used with an already implanted deep brain
      stimulation system. The purpose of this study is to determine if TOPS DBS can improve
      Parkinson's symptoms compared to Standard DBS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 27, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Random order of presentation of all three TOPS and Standard DBS in each participant</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participant and Outcomes Assessor blinded to DBS pattern in use</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Motor score - Off medication/On DBS</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Average difference between the best TOPS and Standard. The MDS-UPDRS Part III is the sum of 33 scores evaluating a set of Parkinson's disease motor symptoms on a scale from 0 to 4 points. A score of 0 indicates no symptom is present and a maximum score of 4 indicates the most severe symptom. The total scale range is 0-132, where higher scores indicate more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study related adverse device effects</measure>
    <time_frame>After 1 week treatment period using TOPS1</time_frame>
    <description>Reported AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study related adverse device effects</measure>
    <time_frame>After 1 week treatment period using TOPS2</time_frame>
    <description>Reported AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study related adverse device effects</measure>
    <time_frame>After 1 week treatment period using TOPS3</time_frame>
    <description>Reported AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study related adverse device effects</measure>
    <time_frame>After 1 week treatment period using Standard</time_frame>
    <description>Reported AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Home Use &quot;On Time&quot;</measure>
    <time_frame>During 1 week treatment period using each pattern</time_frame>
    <description>Home use Parkinson's disease motor symptom diary recording On Time without dyskinesia, On Time with non-troublesome dyskinesia, On Time with troublesome dyskinesia, Off Time, and Asleep Time. Average &quot;On Time&quot; difference between the best TOPS and Standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Rating</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Average difference in Satisfaction between the best TOPS and Standard. Satisfaction is scored on a scale of 1 - 10 where 1 is Not at all satisfied and 10 is Fully satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Medication Use</measure>
    <time_frame>During 1 week treatment period using each pattern</time_frame>
    <description>Parkinson's medication usage recorded in home use medication diary. Average difference between the best TOPS and Standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rest Tremor - Off medication/On DBS</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Measured using Kinesia One system. Average difference between the best TOPS and Standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postural Tremor - Off medication/On DBS</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Measured using Kinesia One system. Average difference between the best TOPS and Standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradykinesia - Off medication/On DBS</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Measured using Kinesia One system. Average difference between the best TOPS and Standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and severity of side effects of stimulation</measure>
    <time_frame>During 1 week treatment period using each pattern</time_frame>
    <description>Proportion of participants experiencing side effects recorded in home use motor symptom diary and clinic. Average difference between the best TOPS and Standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Motor score - On medication/On DBS</measure>
    <time_frame>After 1 week treatment period using each pattern</time_frame>
    <description>Average difference between the best TOPS and Standard. The MDS-UPDRS Part III is the sum of 33 scores evaluating a set of Parkinson's disease motor symptoms on a scale from 0 to 4 points. A score of 0 indicates no symptom is present and a maximum score of 4 indicates the most severe symptom. The total scale range is 0-132, where higher scores indicate more severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>TOPS1 DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive TOPS1 for one week, followed by one week each of TOPS2, TOPS3, and Standard in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOPS2 DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive TOPS2 for one week, followed by one week each of TOPS1, TOPS3, and Standard in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOPS3 DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive TOPS3 for one week, followed by one week each of TOPS1, TOPS2, and Standard in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TOPS1 DBS</intervention_name>
    <description>TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system</description>
    <arm_group_label>Standard DBS</arm_group_label>
    <arm_group_label>TOPS1 DBS</arm_group_label>
    <arm_group_label>TOPS2 DBS</arm_group_label>
    <arm_group_label>TOPS3 DBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TOPS2 DBS</intervention_name>
    <description>TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system</description>
    <arm_group_label>Standard DBS</arm_group_label>
    <arm_group_label>TOPS1 DBS</arm_group_label>
    <arm_group_label>TOPS2 DBS</arm_group_label>
    <arm_group_label>TOPS3 DBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TOPS3 DBS</intervention_name>
    <description>TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system</description>
    <arm_group_label>Standard DBS</arm_group_label>
    <arm_group_label>TOPS1 DBS</arm_group_label>
    <arm_group_label>TOPS2 DBS</arm_group_label>
    <arm_group_label>TOPS3 DBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard DBS</intervention_name>
    <description>Standard is the pattern of stimulation that is usually delivered clinically by a DBS system</description>
    <arm_group_label>Standard DBS</arm_group_label>
    <arm_group_label>TOPS1 DBS</arm_group_label>
    <arm_group_label>TOPS2 DBS</arm_group_label>
    <arm_group_label>TOPS3 DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosed with Parkinson's disease

          -  Implanted with unilateral or bilateral subthalamic DBS System to treat Parkinson's
             disease at least 6 months prior to the study date

          -  Responds to DBS by having demonstrated a minimum improvement in motor score

        Key Exclusion Criteria:

          -  Score of &lt;24 on the Mini Mental Status Exam

          -  Abuses drugs or alcohol

          -  Pregnant

          -  History of significant cardiovascular, pulmonary, musculoskeletal, metabolic, or other
             neurological disorders (i.e. epilepsy, stroke)

          -  Prisoners, employees that report to investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexis Kuncel, PhD</last_name>
    <phone>216.378.9109</phone>
    <phone_ext>508</phone_ext>
    <email>akuncel@deepbraininnovations.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Grill, MS</last_name>
    <phone>216.378.9109</phone>
    <phone_ext>105</phone_ext>
    <email>jgrill@deepbraininnovations.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Derek Ridgeway</last_name>
      <phone>352-733-2427</phone>
      <email>Derek.ridgeway@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Adolfo Ramirez-Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cristal Gomez</last_name>
      <phone>312-926-9912</phone>
      <email>cristal.gomez@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Rosenow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Gauger</last_name>
      <phone>919-668-1538</phone>
      <email>lisa.gauger@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

